Friedhoff and Buxbaum have shown two things: First, they showed that lovastatin could prevent cells from making beta amyloid in the test tube in doses that could be realistically given to patients.
At the very least, the drug is in the hands of top-flight researchers, including Dr. Lawrence Friedhoff , who oversaw the development of the world's most prescribed Alzheimer's treatment, Aricept, while at Japanese drugmaker Eisai .